Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Faes Farma (0K9H) Share Price & Analysis

0K9H Stock Chart & Stats

€4.85€0.08(1.68%)
At close: 12:00 AM GMT
€4.5€4.753 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
EUR 4.79 - EUR 4.88
52-Week Range
EUR 4.33 - EUR 5.48
Previous Close
EUR 4.77
Volume
N/A
Average Volume (3M)
23.43K
Market Cap
EUR 1.50B
Enterprise Value
EUR 1.70B
Total Cash (Recent Filing)
EUR 136.78M
Total Debt (Recent Filing)
EUR 396.85M
Price to Earnings (P/E)
11.1
Beta
0.51
Next Earnings
Feb 26, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
2.63%

Bulls Say, Bears Say

Bulls Say

Historical Profitability

Faes Farma has demonstrated substantial earnings power across several years, providing a durable operating base. Although profitability weakened in 2025, the historical record supports the resilience of its branded pharmaceutical and healthcare portfolio.

Strong Equity Base

A sizable equity base gives Faes Farma financial support and reduces dependence on external funding compared with a highly leveraged business. This provides capacity to sustain operations and invest in its pharmaceutical portfolio despite reduced flexibility.

Established Cash Generation

The company has generally converted its pharmaceutical operations into positive operating and free cash flow, supporting reinvestment and financial obligations. While recent conversion weakened, the multi-year record indicates an underlying ability to generate cash.

Bears Say

Revenue Decline

The 2025 revenue contraction signals weaker demand, product mix, or market execution after a period of steadier growth. If sustained, lower sales would limit operating leverage and make it harder to fund portfolio development and expansion.

Margin Compression

Sharp margin pressure reduces the earnings contribution from each unit of sales and can weaken the company’s ability to absorb cost increases. Persistent compression would challenge the profitability of Faes Farma’s product portfolio.

Higher Leverage And Weaker Cash Conversion

The simultaneous increase in leverage and decline in free cash flow reduces financial flexibility versus Faes Farma’s historically conservative profile. Weaker cash conversion may constrain investment capacity and increase sensitivity to operating setbacks.

Faes Farma News

0K9H FAQ

What was Faes Farma’s price range in the past 12 months?
Faes Farma lowest share price was €4.33 and its highest was €5.48 in the past 12 months.
What is Faes Farma’s market cap?
Faes Farma’s market cap is €1.50B.
When is Faes Farma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Faes Farma’s earnings last quarter?
Faes Farma released its earnings results on Jul 30, 2026. The company reported €0.183 earnings per share for the quarter.
Is Faes Farma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Faes Farma pay dividends?
Faes Farma does not currently pay dividends.
What is Faes Farma’s EPS estimate?
Faes Farma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Faes Farma have?
Faes Farma has 316,223,940 shares outstanding.
What happened to Faes Farma’s price movement after its last earnings report?
Faes Farma reported an EPS of €0.183 in its last earnings report. Following the earnings report the stock price went up 0.527%.
Which hedge fund is a major shareholder of Faes Farma?
Currently, no hedge funds are holding shares in GB:0K9H
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology